Link to this page
Biological and Environmental Research Ontology
Last uploaded:
December 23, 2022
| Id | http://purl.obolibrary.org/obo/NCIT_C88322
http://purl.obolibrary.org/obo/NCIT_C88322
|
|---|---|
| Preferred Name | Docetaxel Formulation CKD-810 |
| Definitions |
An injectable formulation containing the taxane docetaxel, a semisynthetic analogue of paclitaxel, with antineoplastic activity. Docetaxel binds specifically to the beta-tubulin subunit of the microtubule, stabilizing tubulin and inhibiting microtubule disassembly, which results in cell-cycle arrest at the G2/M phase and cell death. This agent also inhibits pro-angiogenic factors such as vascular endothelial growth factor (VEGF) and induces various mediators of the inflammatory response.
|
| Type | http://www.w3.org/2002/07/owl#Class |
All Properties
| definition | An injectable formulation containing the taxane docetaxel, a semisynthetic analogue of paclitaxel, with antineoplastic activity. Docetaxel binds specifically to the beta-tubulin subunit of the microtubule, stabilizing tubulin and inhibiting microtubule disassembly, which results in cell-cycle arrest at the G2/M phase and cell death. This agent also inhibits pro-angiogenic factors such as vascular endothelial growth factor (VEGF) and induces various mediators of the inflammatory response. |
|---|---|
| prefLabel | Docetaxel Formulation CKD-810
|
| label | Docetaxel Formulation CKD-810
|
| NCI_META_CUI | CL413582
|
| PDQ_Closed_Trial_Search_ID | 661020
|
| code | C88322
|
| prefixIRI | NCIT:C88322
|
| in_subset | |
| Preferred_Name | Docetaxel Formulation CKD-810
|
| Maps_To | Docetaxel Formulation CKD-810
|
| NCI_Drug_Dictionary_ID | 661020
|
| type | |
| Is_Value_For_GDC_Property | |
| subClassOf | |
| PDQ_Open_Trial_Search_ID | 661020
|
| Semantic_Type | Pharmacologic Substance
|
| Delete | Subject | Author | Type | Created |
|---|---|---|---|---|
| No notes to display |